Graft-Versus-Host Disease

Published on 05/03/2015 by admin

Filed under Dermatology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1405 times

44

Graft-Versus-Host Disease

Multiorgan disorder that most commonly results from the transfer of donor hematopoietic stem cells into a recipient via an allogeneic hematopoietic stem cell transplant (HSCT).

Despite advances in HSCT procedures and post-transplantation immunosuppressive therapy, more than half of HSCT recipients develop chronic graft-versus-host disease (GVHD), which remains a major cause of morbidity and mortality.

Table 44.1 lists risk factors for GVHD in HSCT recipients.

Less frequent settings of GVHD include transfusion of non-irradiated blood products to an immunocompromised patient, maternal–fetal transmission to an immunodeficient neonate, and solid organ transplantation.

Divided into acute and chronic forms based on clinical features.

Pathogenesis of acute GVHD occurs in three steps: (1) HSCT conditioning regimen leads to epithelial cell injury and activation of host antigen presenting cells; (2) activation of donor T cells; (3) tissue destruction by cytotoxic T cells, natural killer cells, and soluble factors (e.g. tumor necrosis factor-α [TNF-α]).

Chronic GVHD shares features (e.g. autoantibody production, cutaneous sclerosis) with autoimmune connective tissue diseases.

Histologically, acute GVHD and epidermal involvement in chronic GVHD are characterized by variable degrees of keratinocyte necrosis (often accentuated in appendages), vacuolar degeneration of the basal layer, and a band-like lymphocytic infiltrate.

Acute GVHD

Most often arises 4–6 weeks after HSCT with traditional regimens.

Persistent, recurrent, and late-onset variants of acute GVHD can occur during a time period (>100 days post-transplant) traditionally reserved for chronic GVHD, especially following interventions such as tapering of immunosuppression and donor lymphocyte infusions.

Typically presents as a morbilliform exanthem, often with perifollicular accentuation.

Initial predilection for acral sites (e.g. dorsal hands and feet, palms, soles, ears), forearms, and upper trunk.

Clinical staging is based on the proportion of the cutaneous surface involved: Stage 1, <25%; Stage 2, 25–50%; and Stage 3, >50%. Stage 4 represents erythroderma with bullae/epidermal detachment resembling toxic epidermal necrolysis (Fig. 44.1).

Mucosal surfaces (including the conjunctiva), the gastrointestinal tract (nausea, diarrhea, abdominal pain), and the liver (transaminitis, cholestasis) are frequently affected.

Histologic evaluation is helpful but not necessarily diagnostic, and clinicopathologic correlation is essential.

DDx: drug eruption, viral exanthem, engraftment syndrome (nonspecific erythematous eruption, fever, pulmonary edema; onset day 10–14 post transplant), toxic erythema of chemotherapy (especially with palmoplantar or intertriginous involvement).

Rx: topical CS if limited cutaneous involvement only; most patients require systemic CS, which are typically added to ongoing prophylactic treatment with a systemic calcineurin inhibitor; second-line treatments include other immunosuppressive agents (e.g. mycophenolate mofetil [MMF], TNF-α inhibitors).

Chronic GVHD

Can occur as a continuation of acute GVHD, as a recurrence following a GVHD-free interval, or without a history of acute GVHD.

Skin and mucosal involvement are extremely common and highly variable in their presentations (Table 44.2; Fig. 44.2A), and almost any organ system can be affected (Fig. 44.2B).

Reticulate pink to violet papules with scale (lichen planus-like) favoring the dorsal hands and feet, forearms, and trunk represent one characteristic manifestation (Fig. 44.3A).

The spectrum of sclerotic involvement includes.

Lichen sclerosus-like shiny, wrinkled, gray-white plaques, ± follicular plugging, favoring the upper trunk (Fig. 44.3B,C).

Localized or widespread morphea-like indurated, hyperpigmented to skin-colored plaques favoring the lower trunk (Fig. 44.3D).

Eosinophilic fasciitis-like presentations with acute edema and pain evolving into areas of firm skin with subcutaneous rippling (‘pseudo-cellulite’; Fig. 44.3F) and linear depressions following a vein or between muscle groups (groove sign); favors the extremities (sparing the hands and feet) and may result in joint contractures.

Often affects the nails and the oral and genital mucosa (Fig. 44.4; see Table 44.2).

Other frequent sites of involvement include the eyes (keratoconjunctivitis sicca, blepharitis), salivary glands (sicca syndrome), esophagus (strictures), liver, pancreas (exocrine insufficiency), and lungs (bronchiolitis obliterans).

DDx: drug eruption (e.g. lichenoid, photosensitive), autoimmune connective tissue diseases (e.g. lupus erythematosus, morphea), papulosquamous disorders.

Rx: skin-directed with topical CS or calcineurin inhibitors (for superficial disease) or phototherapy (narrowband UVB, UVA1, PUVA); components of systemic combination therapy may include CS, calcineurin inhibitors, imatinib, acitretin, and rituximab; physical therapy (for joint mobility), sun protection, and regular skin examinations, especially if prolonged immunosuppression.

For further information see Ch. 52. From Dermatology, Third Edition.